Bolt Biotherapeutics (NASDAQ:BOLT) Issues Quarterly Earnings Results, Hits Estimates

Bolt Biotherapeutics (NASDAQ:BOLT) announced its quarterly earnings data on Monday. The company reported ($0.38) EPS for the quarter, meeting analysts’ consensus estimates of ($0.38), Zacks reports. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.79 million.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ:BOLT opened at $0.42 on Wednesday. The firm has a market capitalization of $16.07 million, a price-to-earnings ratio of -0.25 and a beta of 0.94. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.16 and a quick ratio of 3.16. The business’s 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.56. Bolt Biotherapeutics has a 12 month low of $0.38 and a 12 month high of $1.56.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BOLT. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday. Stifel Nicolaus cut their price objective on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research report on Tuesday. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $1.13.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.